168 Assembly of Chimeric Antigen Receptor Targeting αVβ6 Expressing Pancreatic Cancer Molecular Therapy Volume 22, Supplement 1, May 2014 Copyright © The American Society of Gene & Cell Therapy S63[.]
CANCER-IMMUNOTHERAPY I CNA12-CTLs persisted longer, homed to the tumour and expanded more than eGFP-CTLs in mice treated with FK506 (P98% apoptosis after 24 hrs, while control CAR+ T-cells remained unaffected Finally, we performed experiments in vivo in NSG mice reconstituted with human-cord blood derived CD34+ cells Upon engraftment of human B cells, HLA mismatched FireFly-Luciferase-labelled CAR-iC+ T-cells (5x106) were infused i.v and their persistence monitored by IVIS imaging CAR-iC+ T cells completely eliminated B cells in association with a concomitant expansion of T cells As B-cell aplasia occurred, CARiC+ T cells subsequently contracted, even if bioluminescent signals remained detectable for >3 months, and T-cells were detectable in peripheral blood, spleen and bone marrow by flow cytometry At the peak of T-cell expansion, with corresponding B-cell aplasia, a group of mice received one single dose of CID (50μg/mouse) This resulted in a rapid (